Press release: TeleVet
TeleVet, Inc., a leading provider of technology solutions for veterinary teams that increase productivity, reduce staff burnout and improve the customer experience, and Boehringer Ingelheim Animal Health USA Inc. (Boehringer Ingelheim), a global innovator leader in animal health products for pets, horses and livestock, recently announced a strategic collaboration to provide innovative technology and services that will make it easier for veterinary practices to provide the best patient care while reducing stress on their teams.
As part of the collaboration, Boehringer Ingelheim has invested in TeleVet and Randolph Legg, President and Chief Business Officer of Boehringer Ingelheim Animal Health USA Inc., will join TeleVet’s Board of Directors.
Veterinarians and their teams are under more pressure than ever. The number of pet owners has increased during COVID-19, while staffing shortages and industry consolidation have led to longer days, high staff turnover and increased financial pressures. Technology solutions that automate daily tasks and create operational efficiencies while maintaining quality of care have never been more essential in today’s veterinary practices.
TeleVet, an Austin-based startup backed by Mercury Fund and other notable investors, provides veterinary management technology solutions used by thousands of veterinarians through TeleVet’s flagship product in the United States, Flow, is a management tool integrated case management that automates routine tasks and simplifies communications, scheduling and payments.
This collaboration will leverage TeleVet’s advanced technology to increase practice management efficiency and enable veterinarians to seamlessly engage with patients and pet owners. TeleVet will become Boehringer Ingelheim’s preferred veterinary health technology platform in the United States, and TeleVet will leverage the investment of Boehringer Ingelheim and its highly respected business team to quickly bring innovative solutions designed specifically for the market to market. team and the veterinary industry. Existing PetPro Connect customers will experience no service disruption as Boehringer Ingelheim and TeleVet teams work together to create the premier veterinary platform of the future.
“We are delighted to begin our new collaboration with Boehringer Ingelheim, a global leader in animal health with an exceptionally strong network and a shared commitment to the well-being of veterinary practitioners and patients,” said Zeynep Young, CEO of TeleVet. . “We are honored to have them recognize our leadership in the industry. Their strategic insight, resources and extensive client relationships will help us accelerate our mission to improve the lives of veterinary professionals by simplifying time-consuming and demanding day-to-day clinic operations. This will allow clinics to provide the best possible patient care.
“We recognize that in today’s environment, veterinary practices need technology that allows them to more easily focus on the practice of medicine,” said Legg. “At Boehringer Ingelheim Animal Health, we take our responsibility seriously as a trusted partner of veterinary teams and we will continue to invest in the best products and services. After evaluating all of the technology solutions available to veterinary practices, we found that TeleVet’s quality, current and future innovation, progressive leadership team, and strong focus on veterinary teams put them above all other competitors.
TeleVet is a leading provider of technology solutions that increase team productivity, reduce staff burnout, improve the customer experience and ultimately allow veterinary teams to focus on what they are most passionate about: delivering quality care. . Flow, the company’s flagship product, is an integrated case management tool that automates routine tasks and simplifies communications, scheduling and payments. TeleVet, founded in 2017, currently automates over one million tasks per year for thousands of veterinary teams nationwide.
Making new and better medicines for humans and animals is at the heart of what Boehringer Ingelheim does. Its mission is to create breakthrough therapies that change lives. Since its foundation in 1885, Boehringer Ingelheim has been an independent, family-owned company. The company has the freedom to pursue its long-term vision, looking ahead to identify future health challenges and targeting areas of need where it can do the most good.
As a world leader in the research-based pharmaceutical industry, with around 52,000 employees, Boehringer Ingelheim creates value every day through innovation in its three business areas: human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
In 2020, Boehringer Ingelheim achieved net sales of approximately $22.33 billion (€19.57 billion). Its significant investment of more than $4.2 billion (€3.7 billion) in 2020 (18.9% of net sales) in R&D is driving innovation, enabling the next generation of medicines that save lives and improve the quality of life.